Uncovering the DNA methylome in chronic lymphocytic leukemia

Epigenetics

Volumn 8, Issue 2, 2013, Pages 138-148

  Cahill, Nicola ^a   Rosenquist, Richard ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Chronic lymphocytic leukemia; CpG islands; Gene silencing; Hypermethylation; Hypomethylation; Microarrays; Next generation sequencing

Indexed keywords

CD38 ANTIGEN; CRYPTOCHROME 1; DEATH ASSOCIATED PROTEIN KINASE; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOID ENHANCER FACTOR 1; MICRORNA 124; MICRORNA 155; MICRORNA 34A; MICRORNA 9; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; PROTEIN MYB; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; SLIT PROTEIN; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VON HIPPEL LINDAU PROTEIN;

CHRONIC LYMPHATIC LEUKEMIA; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; EPIGENETICS; GENE ACTIVATION; GENOMIC INSTABILITY; HUMAN; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84874347712     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.23439     Document Type: Review

References (90)

1. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10:37-50; PMID:19956173.
2. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168-74; PMID:10729832; http://dx.doi. org/10.1016/S0168-9525(99)01971-X.
3. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16:6-21; PMID:11782440; http://dx.doi.org/10.1101/gad.947102.
4. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009; 10:295-304; PMID:19308066; http:// dx.doi.org/10.1038/nrg2540.
5. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002; 99:3740-5; PMID:11891299; http://dx.doi.org/10.1073/pnas.052410099.
6. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007; 16(Spec No 1):R50-9; PMID:17613547; http://dx.doi. org/10.1093/hmg/ddm018.
7. Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007; 6:1001-5; PMID:17457051; http://dx.doi.org/10.4161/ cc.6.9.4209.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28; PMID:12042769.
9. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300:455; PMID:12702868; http://dx.doi.org/10.1126/science. 1083557.
10. Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, Morales C, et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 2006; 66:8462-9468; PMID:16951157; http://dx.doi. org/10.1158/0008-5472.CAN-06-0293.
11. Lipsanen V, Leinonen P, Alhonen L, Jänne J. Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia. Blood 1988; 72:2042-4; PMID:2904292.
12. Wahlfors J, Hiltunen H, Heinonen K, Hämäläinen E, Alhonen L, Jänne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 1992; 80:2074-80; PMID:1382719.
13. Fabris S, Bollati V, Agnelli L, Morabito F, Motta V, Cutrona G, et al. Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics 2011; 6:188-94; PMID:20930513; http:// dx.doi.org/10.4161/epi.6.2.13528.
14. Kulis M, Heath S, Bibikova M, Queirós AC, Navarro A, Clot G, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012; 44:1236-42; PMID:23064414; http://dx.doi.org/10.1038/ng.2443.
15. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82:1820-8; PMID:8104532.
16. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997; 3:2025-32; PMID:9815593.
17. Yuille MR, Condie A, Stone EM, Wilsher J, Bradshaw PS, Brooks L, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 2001; 30:336-41; PMID:11241786; http://dx.doi.org/10.1002/ gcc.1099.
18. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood 2000; 95:3208-13; PMID:10807790.
19. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14:6107-15; PMID:8557030.
20. Seeliger B, Wilop S, Osieka R, Galm O, Jost E. CpG island methylation patterns in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50:419-26; PMID:19347729; http://dx.doi. org/10.1080/10428190902756594.
21. Bechter OE, Eisterer W, Dlaska M, Kühr T, Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol 2002; 30:26-33; PMID:11823034; http://dx.doi.org/10.1016/S0301-472X(01)00760-3.
22. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005; 23:3877-85; PMID:15809452; http://dx.doi.org/10.1200/ JCO.2005.02.196.
23. Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz OJ, et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005; 90:1078-88; PMID:16079107.
24. Chantepie SP, Vaur D, Grunau C, Salaün V, Briand M, Parienti JJ, et al. ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia. Leuk Res 2010; 34:800-8; PMID:19944462; http://dx.doi.org/10.1016/j.leukres. 2009.10.018.
25. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu LB, Zucknick M, et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 2012; 30:2483-91; PMID:22564988; http://dx.doi. org/10.1200/JCO.2011.39.3090.
26. Strathdee G, Sim A, Parker A, Oscier D, Brown R. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia 2006; 20:1326-9; PMID:16688227; http://dx.doi.org/10.1038/sj.leu.2404254.
27. Cillo C, Cantile M, Faiella A, Boncinelli E. Homeobox genes in normal and malignant cells. J Cell Physiol 2001; 188:161-9; PMID:11424082; http://dx.doi. org/10.1002/jcp.1115.
28. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 2007; 13:5048-55; PMID:17785556; http://dx.doi.org/10.1158/1078-0432.CCR-07-0919.
29. Irving L, Mainou-Fowler T, Parker A, Ibbotson RE, Oscier DG, Strathdee G. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia. Epigenetics 2011; 6:300-6; PMID:21051931; http://dx.doi.org/10.4161/ epi.6.3.14038.
30. Fülöp Z, Csernus B, Tímár B, Szepesi A, Matolcsy A. Microsatellite instability and hMLH1 promoter hypermethylation in Richter's transformation of chronic lymphocytic leukemia. Leukemia 2003; 17:411-5; PMID:12592341; http://dx.doi.org/10.1038/ sj.leu.2402792.
31. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129:879-90; PMID:17540169; http://dx.doi.org/10.1016/j.cell.2007.03.043.
32. Hanoun M, Eisele L, Suzuki M, Greally JM, Hüttmann A, Aydin S, et al. Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS One 2012; 7:e34347; PMID:22470559; http://dx.doi. org/10.1371/journal.pone.0034347.
33. Dunwell TL, Dickinson RE, Stankovic T, Dallol A, Weston V, Austen B, et al. Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics 2009; 4:265-9; PMID:19550140.
34. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006; 66:653-8; PMID:16423993; http://dx.doi.org/10.1158/0008-5472.CAN-05-3712.
35. Chim CS, Pang R, Liang R. Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia. J Clin Pathol 2008; 61:1214-9; PMID:18765431; http://dx.doi.org/10.1136/ jcp.2008.060152.
36. Moskalev EA, Luckert K, Vorobjev IA, Mastitsky SE, Gladkikh AA, Stephan A, et al. Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia. BMC Cancer 2012; 12:213; PMID:22672427; http://dx.doi. org/10.1186/1471-2407-12-213.
37. Shinawi T, Hill V, Dagklis A, Baliakas P, Stamatopoulos K, Agathanggelou A, et al. KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia. Epigenetics 2012; 7:211-5; PMID:22430796; http:// dx.doi.org/10.4161/epi.7.3.19222.
38. Lyko F, Stach D, Brenner A, Stilgenbauer S, Döhner H, Wirtz M, et al. Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis 2004; 25:1530-5; PMID:15188237; http://dx.doi.org/10.1002/elps.200305830.
39. Yu MK, Bergonia H, Szabo A, Phillips JD. Progressive disease in chronic lymphocytic leukemia is correlated with the DNA methylation index. Leuk Res 2007; 31:773-7; PMID:16970987; http://dx.doi. org/10.1016/j.leukres.2006.07.007.
40. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004; 64:2424-33; PMID:15059895; http://dx.doi.org/10.1158/0008-5472.CAN-03-2870.
41. Rahmatpanah FB, Carstens S, Hooshmand SI, Welsh EC, Sjahputera O, Taylor KH, et al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics 2009; 1:39-61; PMID:20495622; http:// dx.doi.org/10.2217/epi.09.10.
42. Cahill N, Bergh AC, Kanduri M, Goransson-Kultima H, Mansouri L, Isaksson A, et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2013; 27:150-8; PMID:22922567.
43. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 2010; 5:499-508; PMID:20484983; http://dx.doi.org/10.4161/ epi.5.6.12179.
44. Kanduri M, Cahill N, Göransson H, Enström C, Ryan F, Isaksson A, et al. Differential genome-wide arraybased methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010; 115:296-305; PMID:19897574; http://dx.doi.org/10.1182/ blood-2009-07-232868.
45. Kanduri M, Marincevic M, Halldórsdóttir AM, Mansouri L, Junevik K, Ntoufa S, et al. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subsetbiased global DNA methylation profiles. Epigenetics 2012; 7:1435-42; PMID:23154584; http://dx.doi. org/10.4161/epi.22901.
46. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86; PMID:19151715; http://dx.doi. org/10.1038/ng.298.
47. Halldórsdóttir AM, Sander B, Göransson H, Isaksson A, Kimby E, Mansouri M, et al. High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes Cancer 2011; 50:113-21; PMID:21117067; http:// dx.doi.org/10.1002/gcc.20836.
48. Pei LR, Choi JH, Liu JM, Lee EJ, McCarthy B, Wilson JM, et al. Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics 2012; 7:567-78; PMID:22534504; http://dx.doi.org/10.4161/ epi.20237.
49. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010; 31:745-50; PMID:20118199; http://dx.doi. org/10.1093/carcin/bgq033.
50. Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R, et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011; 6:e19027; PMID:21544199; http://dx.doi. org/10.1371/journal.pone.0019027.
51. Baer C, Claus R, Frenzel LP, Zucknick M, Park YJ, Gu L, et al. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res 2012; 72:3775-85; PMID:22710432; http://dx.doi.org/10.1158/0008-5472.CAN-12-0803.
52. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524-9; PMID:12434020; http://dx.doi. org/10.1073/pnas.242606799.
53. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20:425-37; PMID:17707831; http:// dx.doi.org/10.1016/j.beha.2007.02.003.
54. Nicoloso MS, Kipps TJ, Croce CM, Calin GA. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 2007; 139:709-16; PMID:18021085; http://dx.doi.org/10.1111/j.1365-2141.2007.06868.x.
55. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114:3872-9; PMID:19717645; http:// dx.doi.org/10.1182/blood-2009-06-229211.
56. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17:28-40; PMID:20060366; http://dx.doi.org/10.1016/j. ccr.2009.11.019.
57. Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114:2589-97; PMID:19643983; http://dx.doi.org/10.1182/blood-2009-05-224071.
58. Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med 2011; 15:2760-7; PMID:21323860; http:// dx.doi.org/10.1111/j.1582-4934.2011.01274.x.
59. Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 2009; 114:3255-64; PMID:19692702; http://dx.doi.org/10.1182/blood-2009-06-229898.
60. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; PMID:19752007; http://dx.doi.org/10.1093/carcin/bgp220.
61. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2009; 106:13433-8; PMID:19666576; http://dx.doi. org/10.1073/pnas.0906455106.
62. Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC, et al. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle 2009; 8:3663-7; PMID:19901553; http:// dx.doi.org/10.4161/cc.8.22.9957.
63. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92:1242-5; PMID:17666364; http://dx.doi. org/10.3324/haematol.10720.
64. Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011; 96:1161-9; PMID:21546498; http://dx.doi.org/10.3324/haematol. 2010.039768.
65. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112:4202-12; PMID:18713946; http://dx.doi. org/10.1182/blood-2008-03-147645.
66. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 2010; 12:1108-14; PMID:20935635; http:// dx.doi.org/10.1038/ncb2116.
67. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-6; PMID:20601953; http:// dx.doi.org/10.1038/ng.621.
68. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43:309-15; PMID:21399634; http://dx.doi.org/10.1038/ng.788.
69. Kn H, Bassal S, Tikellis C, El-Osta A. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL). Cancer Biol Ther 2004; 3:989-94; PMID:15467427; http:// dx.doi.org/10.4161/cbt.3.10.1137.
70. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104:15805-10; PMID:17890317; http:// dx.doi.org/10.1073/pnas.0707628104.
71. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 2010; 107:12210-5; PMID:20566844; http://dx.doi. org/10.1073/pnas.1007186107.
72. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119:1162-72; PMID:22096249; http://dx.doi.org/10.1182/blood-2011-05-351510.
73. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A 2012; 109:2555-60; PMID:22308499; http://dx.doi. org/10.1073/pnas.1200003109.
74. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007; 448:714-7; PMID:17687327; http://dx.doi. org/10.1038/nature05987.
75. Amin S, Walsh M, Wilson C, Parker AE, Oscier D, Willmore E, et al. Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. J Cell Mol Med 2012; 16:2074-84; PMID:22151263; http://dx.doi. org/10.1111/j.1582-4934.2011.01503.x.
76. Billot K, Soeur J, Chereau F, Arrouss I, Merle-Béral H, Huang ME, et al. Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood 2011; 117:1917-27; PMID:21139082; http://dx.doi.org/10.1182/blood-2010-09-307140.
77. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011; 117:862-71; PMID:21098398; http://dx.doi.org/10.1182/blood-2010-05-284638.
78. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 2007; 13:3174-81; PMID:17545520; http://dx.doi. org/10.1158/1078-0432.CCR-06-1720.
79. Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, et al. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 2011; 118:6132-40; PMID:22001392; http://dx.doi. org/10.1182/blood-2011-01-323147.
80. Moreno P, Abreu C, Borge M, Morande P, Pegazzano M, Palacios F, et al. Lipoprotein lipase expression in unmutated CLL patients is the consequence of a demethylation process induced by the microenvironment. Leukemia 2012; In Press; PMID:22828442; http://dx.doi.org/10.1038/leu.2012.212.
81. Kaderi MA, Kanduri M, Buhl AM, Sevov M, Cahill N, Gunnarsson R, et al. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Haematologica 2011; 96:1153-60; PMID:21508119; http://dx.doi. org/10.3324/haematol.2010.039396.
82. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Dürig J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209:2183-98; PMID:23091163; http://dx.doi.org/10.1084/jem.20120833.
83. Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol 2006; 76:455-64; PMID:16529606; http://dx.doi. org/10.1111/j.0902-4441.2005.t01-1-EJH2530.x.
84. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208:1389-401; PMID:21670202; http://dx.doi.org/10.1084/ jem.20110921.
85. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002; 21:3172-80; PMID:12082632; http://dx.doi. org/10.1038/sj.onc.1205462.
86. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-20; PMID:8493574; http://dx.doi.org/10.1126/science. 8493574.
87. Matsuda S, Yokozaki S, Yoshida H, Kitagishi Y, Shirafuji N, Okumura N. Insulin receptor substrate protein 53 (IRSp53) as a binding partner of antimetastasis molecule NESH, a member of Abelson interactor protein family. Ann Oncol 2008; 19:1356-7; PMID:18480067; http://dx.doi.org/10.1093/annonc/ mdn293.
88. Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011; 117:3816-25; PMID:21296997; http:// dx.doi.org/10.1182/blood-2010-05-285064.
89. Gutierrez A Jr., Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM 3rd, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010; 116:2975-83; PMID:20595513; http://dx.doi.org/10.1182/blood-2010-02-269878.
90. Moreno DA, Scrideli CA, Cortez MA, de Paula Queiroz R, Valera ET, da Silva Silveira V, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010; 150:665-73; PMID:20636436; http://dx.doi.org/10.1111/j.1365-2141.2010.08301.x.